Screener
Rigel Pharmaceuticals RIGL Share Buybacks
Share Buybacks at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Financing activities | ||
| Principal payments of term loans | (7,500) | — |
| Net proceeds from issuance of common stock under equity plans | 321 | 484 |
| Repurchases of common stock in connection with employee tax withholding on RSU vesting | (3,740) | — |
| Net cash (used in) provided by financing activities | (10,919) | 484 |
| Net decrease in cash, cash equivalents and restricted cash | (16,169) | (10,961) |
| Cash, cash equivalents, and restricted cash at beginning of period | 40,637 | 56,746 |
| Cash, cash equivalents, and restricted cash at end of period | $24,468 | $45,785 |
Item 1. Financial Statements
FAQ
- What is Rigel Pharmaceuticals's share buybacks?
- Rigel Pharmaceuticals (RIGL) reported share buybacks of $3.74M in Q1 2026.
- What does share buybacks mean?
- Cash used to buy back the company's own shares on the open market or through structured programs, reducing shares outstanding.
Ask your AI about Rigel Pharmaceuticals's share buybacks.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude